Use of the dopamine receptor agonist Mirapex in the treatment of Parkinson’s disease-Reference-Cited by-同舟云学术

Use of the dopamine receptor agonist Mirapex in the treatment of Parkinson’s disease

Published:2007-07 Issue:6 Volume:37 Page:539-546
ISSN:0097-0549
Container-title:Neuroscience and Behavioral Physiology
language:en
Short-container-title:Neurosci Behav Physiol

Author:

Fedorova N. V.,Chigir’ I. P.

Publisher

Springer Science and Business Media LLC

Subject

General Neuroscience

Link

http://link.springer.com/content/pdf/10.1007/s11055-007-0050-3.pdf

Reference59 articles.

1. V. L. Golubev, Ya. I. Levin, and A. M. Vein, Parkinson’s Disease and Parkinsonism Syndrome [in Russian], MEDpress, Moscow (1999).

2. M. R. Nodel’, D. V. Artem’ev, and N. N. Yakhno, “The efficacy of the dopamine agonist Mirapex in Parkinson’s disease,” Nevrol. Zh., 4, 45–49 (1999).

3. N. V. Fedorova and V. N. Shtok, “Strategy and tactics in the treatment of Parkinson’s disease,” Konsilium, 3, No. 5, 237–242 (2001).

4. V. N. Shtok and N. V. Fedorova, The Treatment of Parkinsonism [in Russian], Moscow (1997).

5. V. N. Shtok and N. V. Fedorova, “Current concepts in the treatment of parkinsonism,” Rus. Med. Zh., 6, No. 13, 837–844 (1998).

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pharmacological Treatments of Parkinson's Disease;Experimental and Clinical Evidence of the Neuropathology of Parkinson’s Disease;2023-08-04

2. Parkinson's disease: Current drug therapy and unraveling the prospects of nanoparticles;Journal of Drug Delivery Science and Technology;2020-08

3. 2-Aminothiazoles;Privileged Structures in Drug Discovery;2018-03-09

4. Impact of Pharmacotherapy on Quality of Life in Patients with Parkinson’s Disease;CNS Drugs;2015-05

5. Experimental Models of l-DOPA-Induced Dyskinesia;International Review of Neurobiology;2011